Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/43049


Allergan: Performance, Products, Pipeline and Potential


Description: Allergan, with headquarters in Irvine, CA, is a global specialty pharmaceutical company that develops and commercialises products for neurosciences, ophthalmology, medical dermatology, medical aesthetics, obesity intervention, urologics and other specialty markets. In addition to its discovery-to-development research programmes, Allergan has global marketing and sales capabilities in over 100 countries.

Allergan has chosen a distinct company strategy, focusing strongly on the development and marketing of speciality products. This tactic seems to have proved effective, with Allergan achieving a market leadership position in the area of neuromodulators with Botox, and in ophthalmology with its range of eye care therapeutics. In 2007, Allergan announced the takeover of Esprit Pharma Holding, which traditionally focuses on the field of urology, signalling a new area of focus for Allergan. The acquisition of Inamed should ensure Allergan maintains a strong presence in the field of medical aesthetics as well.

Botox is the company’s main growth driver, accounting for over a third of company revenue with sales in excess of US$1.3 billion. Allergan’s strong dependence on one key product may seem a concern, however, the company continues to invest signficantly in Botox, with four line extensions currently in the R&D pipeline, further expanding the therapeutic market presence of the product. At present, Botox has few competitors in its marketed indications, however, Solstice Neurosciences is developing Myobloc/Neurobloc (botulinum toxin type B), which has been shown in trials to be as effective as Botox in certain indications. The launch of Myobloc may form the first significant threat to Allergan’s Botox franchise. Indeed, performance thus far in 2009 suggests that fiscal 2009 could be the first year of sales decline for Botox and Allergan will need to rapdily develop new medicinal indications for the product in order to see off its emerging competitiors.

In recent years, Allergan’s level of R&D expenditure has fluctuated significantly. In 2003, the company invested 43.5 per cent of its revenue in R&D. In fiscal 2008, this ratio has fallen to 18.1 per cent, however, it remains higher than the market average of approximately 14 per cent. Allergan’s research remains highly focused and concentrated mainly into three key therapeutic areas. As already mentioned, much of Allergan’s research efforts are centred on maximising the value of Botox, however, the company has also nurtured several novel candidate compounds which may form the basis for long-term growth. Ophthalmology remains the key area of research, and the company’s three most promising projects, Panzem, diquafosol and Posurdex, all fall into this field. Furthermore, the company has several broad research agreements in place, cented mainly on ophthalmology, pain and the treatment of neurodegenerative diseases.


Contents: CONTENTS:
Latest Results

EXECUTIVE SUMMARY
Introduction
Current Financial Position
Business Segment Performance
Geographic Segment Performance
Company Strategy
Acquisitions and Divestitures
Acquisitions
Divestitures
Key Agreements
Discontinued Agreements
Product Performance Forecasts
Pipeline Analysis
Conclusions

THER APEUTIC AREA FOCUS

R&D PIPELINE

NEUROSCIENCES
Marketed Products
Botox/Dysport
R&D Projects
AGN 203818
AGN 323
Growth Forecast

OPHTHALMOLOGY
Marketed Products
Alphagan/Alphagan P
Lumigan
Posurdex/Osurdex
Restasis
Others
R&D Projects
AGN-745 (Sirna-027)
Androgen Tear
Diquafosol
Panzem
Growth Forecast

UROLOGY
Sanctura
R&D Projects
Growth Forecasts

MEDICAL DERMATOLOGY
Marketed Products
Growth Forecast

OTHERS
R&D Projects
EOquin

APPENDIX 1 - FINANCIAL PERFORMANCE
Full Year Results 2008

APPENDIX 2 - KEY AGREMENTS
Acadia Pharmaceuticals Inc
Asterand
Boehringer Ingelheim
EntreMed Inc
ExonHit Therapeutics SA
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Inspire Pharmaceuticals Inc
ISTA Pharmaceuticals Inc
Ivivi Technologies
Kyorin Pharmaceutical Co Ltd
Ligand Pharmaceuticals Inc
Merck & Co
Merz + Co GmbH & Co
Miotech Inc
Novartis
Polyphor Ltd
Pfizer
Sanwa Kagaku Kenkyusho Co Ltd
Senju Pharmaceutical Co Ltd
SkinMedica Inc
Spectrum Pharmaceuticals Inc
Stiefel Laboratories Inc
Syntaxin Ltd
Valeant Pharmaceuticals International
Other

APPENDIX 3 - INFRASTRUCTURE
Manufacturing Facilities
R&D Facilities

APPENDIX 4 - MAJOR PHARMACEUTICAL

SUBSIDIARIES/JOINT VENTURES
Joint-venture Company

APPENDIX 5 - PRODUCT INDEX

INDEX OF TABLES;

Principal Operating Results
Sales By Business Area
Sales By Origin
Long-Lived Assets By Geographical Area
Recent Product Approvals
Major Products, Therapeutic Areas and Sales
Major Neurosciences Products, 2008
Major Ophthalmology Products, 2008

INDEX OF CHARTS:

Sales, Costs and Operating Income
Sales By Business Area, 2008
Sales by Origin
Sales of Major Products (2003A-2013E)
Top Selling Products, 2008
Botox Sales (2003A-2013E)
Alphagan Franchise Sales (2003A-2013E)
Lumigan Sales (2003A-2013E)
Posurdex Sales (2009E-2013E)
Restasis Sales (2003A-2013E)
Diquafosol Sales (2009E-2013E)
Sanctura Sales (2007A-2013E)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity


Summary: Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.


Companies Mentioned - Acadia Pharmaceuticals Inc - Asterand - Boehringer Ingelheim - EntreMed Inc - ExonHit Therapeutics SA - GlaxoSmithKline - Indevus Pharmaceuticals Inc - Inspire Pharmaceuticals Inc - ISTA Pharmaceuticals Inc - Ivivi Technologies - Kyorin Pharmaceutical Co Ltd - Ligand Pharmaceuticals Inc - Merck & Co - Merz + Co GmbH & Co - Miotech Inc - Novartis - Pfizer - Sanwa Kagaku Kenkyusho Co Ltd - Senju Pharmaceutical Co Ltd - Stiefel Laboratories Inc - Syntaxin Ltd - Valeant Pharmaceuticals International


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/43049

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 12/02/2012 18:03:26
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Allergan: Performance, Products, Pipeline and Potential
Web Address:
http://www.researchandmarkets.com/reports/43049
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €745.00 + EUR€ 50.00 Shipping/Handling *
Electronic (PDF) - Single User €745.00
Online Access - Enterprisewide €4,850.00
Electronic (PDF) - Enterprisewide €4,850.00
Online Access - Single User €745.00
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 12/02/2012 18:03:26

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)